BOSTON--(BUSINESS WIRE)--Feb. 4, 2015--
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is
developing innovative and proprietary treatments for nocturnal leg
cramps and spasms associated with severe neuromuscular conditions, today
announced the closing of its initial public offering of 5,400,000 shares
of common stock at a public offering price of $16.00 per share,
resulting in gross proceeds of $86.4 million, before underwriting
discounts and commissions. All of the shares in the offering were sold
by Flex Pharma. The company’s shares began trading on The NASDAQ Global
Market on Thursday, January 29, 2015 under the ticker symbol “FLKS.”
Jefferies LLC and Piper Jaffray & Co. acted as joint book-running
managers. JMP Securities LLC acted as lead manager and Cantor Fitzgerald
& Co. and Roth Capital Partners, LLC acted as co-managers for the
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on January 28, 2015.
This offering was made only by means of a prospectus. Copies of the
final prospectus relating to this offering may be obtained by
contacting: Jefferies LLC, Attn: Equity Syndicate Prospectus Department,
520 Madison Ave, 2nd Floor, New York, NY 10022, by telephone at (877)
547-6340 or by email at Prospectus_Department@Jefferies.com;
or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet
Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or
by email at email@example.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities, in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for nocturnal leg cramps and
spasms associated with severe neuromuscular conditions. In three
randomized, blinded, placebo-controlled, cross-over studies, Flex
Pharma's proprietary treatment has shown a statistically significant
reduction in the intensity of muscle cramps in healthy normal
volunteers. In the second quarter of 2015, the Company intends to
initiate at least one human proof-of-concept study of its proprietary
treatment for individuals with nocturnal leg cramps.
Flex Pharma was founded by National Academy of Science members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications